<DOC>
	<DOCNO>NCT00213291</DOCNO>
	<brief_summary>This study determine safety effectiveness Darbepoetin ( Aranesp ) give every 14 28 day treat low red blood cell child chronic kidney failure .</brief_summary>
	<brief_title>Darbepoetin Treatment Anemia Children With Chronic Renal Failure</brief_title>
	<detailed_description>Erythropoietin ( EPO ) glycoprotein synthesize kidney regulate rate proliferation differentiation red blood cell precursor . The main cause anemia child chronic renal failure deficiency EPO production result decline renal function . Recombinant human EPO ( rHuEPO ) synthetic erythropoietin structurally functionally similar naturally occur EPO . Treatment anemia use rHuEPO associate improvement quality life patient , likely attributable increase production hemoglobin reduction dilatation heart . Recently , analogue EPO two extra oligosaccharide chin , darbepoetin alfa , describe prolonged effect require le frequent dosing . There currently data available efficacy darbepoetin alfa administer every 14-28 day child . The common dosing schedule clinical trial HSC every 7 , 10 , 14 day . Due report increase pain associate SC injection , confusion caregiver 10 day dose schedule necessary , goal current proposal : 1 ) Decrease frequency SC injection 2 ) Eliminate 10 day dose schedule administration Darbepoetin .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>diagnosis chronic renal insufficiency end stage renal disease ( ESRD ) require dialysis clinically stable hemoglobin 110125 g/L screening period ; naive subject , hemoglobin &lt; 110 g/L iron deficient ( TSAT &gt; 19.5 % ) within 4 week study entry stable darbepoetin alpha therapy administer IV SC q7 q21 day OR darbepoetin alpha naive write informed consent parent/legal guardian le 18 year old weight least 10 kg female childbearing potential must practice adequate contraception availability followup assessment schedule live donor kidney transplant within 12 week sign consent uncontrolled blood pressure judge principal investigator change seizure pattern past 30 day ; grandmal seizure 12 week enrollment current clinical evidence severe hyperparathyroidism major surgery 2 week sign consent active inflammatory disease condition require immunosuppressive therapy currently receive antibiotic active systemic infection peritoneal dialysis patient episode peritonitis within past 30 day know HIV antibody positivity know antibody rHuEPO know aluminum toxicity know red cell aplasia know malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>chronic kidney failure</keyword>
	<keyword>darbepoetin</keyword>
	<keyword>pediatrics</keyword>
	<keyword>anemia</keyword>
</DOC>